![]() It also received FDA authorization of an Ampligen study (AMP-518) for post-COVID conditions / persistent myalgic encephalomyelitis / chronic fatigue syndrome-like symptoms often referred to by patients as “long hauler syndrome.” The Immuno-pharma company also published an abstract at the American Association for Cancer Research (AACR) annual meeting in 2022 of positive data from a Phase 1 study in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, which includes Ampligen as a key component, and Keytruda.Īnother abstract at the AACR annual meeting showed positive interim data from a Phase 2 study, which indicates significant survival advantage when Ampligen is combined with Cisplatin and Keytruda in advanced recurrent ovarian cancer, according to the company.ĪIM ImmunoTech said it made regulatory advances, including the US Food and Drug Administration’s authorization of Ampligen in a Phase 2 study (AMP-270) of locally advanced pancreatic cancer following FOLFIRINOX. Over the past year, the Ocala, Florida-based company said it has progressed significantly to achieving multiple clinical and regulatory advances.Ĭlinical milestones included the publication in Cancers of an early access program sponsored by the Dutch government which showed improvement in survival of locally advanced and metastatic pancreatic cancer patients with Ampligen as a single agent maintenance therapy following standard of care FOLFIRINOX. He noted that shareholders didn’t support an advisory vote on the approval of executive compensation at the past two annual meetings. The corporate governance enhancements we are announcing today are designed to further strengthen our board through the addition of new independent directors with in-depth knowledge of biotechnology commercialization and diverse backgrounds, and to further align the company’s leadership with AIM’s performance and the best interests of all shareholders,” Mitchell said in a statement. “We value engagement with our shareholders and their thoughtful and constructive input, and we intend to continue these discussions in the year ahead. READ: AIM ImmunoTech's product candidate Ampligen granted FDA Orphan Drug Designation for treatment of Ebola If appropriate, the committee will then consider making adjustments.ĪIM board chair William Mitchell said the actions are in response to feedback from shareholders at the recent annual meeting. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.ĪIM ImmunoTech Inc (NYSE:AIM) said it will add two directors to its board to bring diversity and additional biotechnology commercialization experience.ĪIM ImmunoTech also said its board compensation committee will engage an independent compensation consultant to evaluate the compensation plans currently in place for company executives. Proactive will on occasion use automation and software tools, including generative AI. The team also has access to and use technologies to assist and enhance workflows. Our human content creators are equipped with many decades of valuable expertise and experience. ![]() Proactive has always been a forward looking and enthusiastic technology adopter. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. This is content that excites and engages motivated private investors. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. Her most recent position was with and 's North America news bureau as senior copy editor with management responsibilities. ![]() She has worked at the Winnipeg Free Press in Manitoba, for WAVE: Winnipeg's Health and Wellness magazine with the Winnipeg Regional Health Authority, and at CBC Radio. Susie has held numerous journalistic roles over the years, from reporter through to editor, with side journeys into radio and videography, plus a decade in corporate communications.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |